Cargando…

Exploring the mechanism of resistance to sorafenib in two hepatocellular carcinoma cell lines

Sorafenib has long been the only approved systemic therapy for advanced hepatocellular carcinoma (HCC), but most patients show primary or acquired drug resistance. In the present study, RNA was extracted from sorafenib-resistant and -sensitive clones of the HCC cell lines HepG2 and Huh7. Protein-pro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Zhi, He, Cheng-Zu, Qin, Ya-Qin, Liao, Jian-Jun, Huang, Shang-Tao, Mo, Steven, Li, Hong-Mian, Lin, Jian-Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7762478/ https://www.ncbi.nlm.nih.gov/pubmed/33234725 http://dx.doi.org/10.18632/aging.104195

Ejemplares similares

Transcriptomic characterization reveals prognostic molecular signatures of sorafenib resistance in hepatocellular carcinoma
por: Yuan, Wei, et al.
Publicado: (2021)

Exploration of Sorafenib Influences on Gene Expression of Hepatocellular Carcinoma
por: Wang, Huancheng, et al.
Publicado: (2020)

Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma
por: Zeng, Zhi, et al.
Publicado: (2021)

Transcriptional regulation of NDUFA4L2 by NFIB induces sorafenib resistance by decreasing reactive oxygen species in hepatocellular carcinoma
por: Zhou, Li, et al.
Publicado: (2022)

CT-707 overcomes hypoxia-mediated sorafenib resistance in Hepatocellular carcinoma by inhibiting YAP signaling
por: Chen, Zibo, et al.
Publicado: (2022)

Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity
por: Cabral, Loraine Kay D., et al.
Publicado: (2020)

The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma
por: Xia, Shunjie, et al.
Publicado: (2020)

Autophagy and biotransformation affect sorafenib resistance in hepatocellular carcinoma
por: Zheng, Ruiqi, et al.
Publicado: (2023)

Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma
por: Lai, Yongting, et al.
Publicado: (2019)

Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus
por: Zhang, Zi-Han, et al.
Publicado: (2017)

Co-delivery of sorafenib and metapristone encapsulated by CXCR4-targeted PLGA-PEG nanoparticles overcomes hepatocellular carcinoma resistance to sorafenib
por: Zheng, Ning, et al.
Publicado: (2019)

Efficacy of Sorafenib Combined With Immunotherapy Following Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma: A Propensity Score Analysis
por: Qin, Jian, et al.
Publicado: (2022)

KPNA3 Confers Sorafenib Resistance to Advanced Hepatocellular Carcinoma via TWIST Regulated Epithelial-Mesenchymal Transition
por: Hu, Bo, et al.
Publicado: (2019)

MCM2 promotes the stemness and sorafenib resistance of hepatocellular carcinoma cells via hippo signaling
por: Zhou, Xin, et al.
Publicado: (2022)

The Roles Of Angiogenesis And Cancer Stem Cells In Sorafenib Drug Resistance In Hepatocellular Carcinoma
por: Cheng, Chiung-Chi, et al.
Publicado: (2019)

Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma
por: Kuczynski, Elizabeth A., et al.
Publicado: (2016)

The Role of Non-Coding RNAs in the Sorafenib Resistance of Hepatocellular Carcinoma
por: Hu, Xinyao, et al.
Publicado: (2021)

Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells
por: Shi, Tingting, et al.
Publicado: (2021)

Corrigendum: Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma
por: Lai, Yongting, et al.
Publicado: (2020)

HDLBP Promotes Hepatocellular Carcinoma Proliferation and Sorafenib Resistance by Suppressing Trim71-dependent RAF1 Degradation
por: Yuan, Jingsheng, et al.
Publicado: (2022)

Sorafenib Combined with Cryoablation to Treat Unresectable Hepatocellular Carcinoma
por: Ni, Hong, et al.
Publicado: (2011)

Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines
por: D’Alessandro, Rosalba, et al.
Publicado: (2014)

Sorafenib as first-line treatment for patients with primary hepatocellular carcinoma: an outcome evaluation
por: Nguyen, Dung Thi, et al.
Publicado: (2023)

TNF-α is a potential therapeutic target to overcome sorafenib resistance in hepatocellular carcinoma
por: Tan, Wenliang, et al.
Publicado: (2018)

TAK1 Is a Novel Target in Hepatocellular Carcinoma and Contributes to Sorafenib Resistance
por: Xia, Shunjie, et al.
Publicado: (2021)

Studying the Role and Molecular Mechanisms of MAP4K3 in Sorafenib Resistance of Hepatocellular Carcinoma
por: Shi, Yi, et al.
Publicado: (2020)

Comparative Metabolomic Profiling of Hepatocellular Carcinoma Cells Treated with Sorafenib Monotherapy vs. Sorafenib-Everolimus Combination Therapy
por: Zheng, Jian-feng, et al.
Publicado: (2015)

Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Mousa, Ali Ben
Publicado: (2008)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
por: Furuse, Junji
Publicado: (2008)

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016)

Phase II Study of First‐Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
por: Abou‐Alfa, Ghassan K., et al.
Publicado: (2017)

Serum hsa_circ_0000615 is a prognostic biomarker of sorafenib resistance in hepatocellular carcinoma
por: Zhang, Lunjun, et al.
Publicado: (2022)

The clinical effect and relevant mechanism of combined sorafenib and radiofrequency ablation in the treatment of early small hepatocellular carcinoma
por: Yan, Shi-Yan, et al.
Publicado: (2016)

Y-Box Binding Protein-1 Promotes Epithelial-Mesenchymal Transition in Sorafenib-Resistant Hepatocellular Carcinoma Cells
por: Liao, Li-Zhu, et al.
Publicado: (2020)

AG-1024 Sensitizes Sorafenib-Resistant Hepatocellular Carcinoma Cells to Sorafenib via Enhancing G1/S Arrest
por: Zhou, Wei, et al.
Publicado: (2021)

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
por: Lai, You-Liang, et al.
Publicado: (2022)

The Enhanced Metastatic Potential of Hepatocellular Carcinoma (HCC) Cells with Sorafenib Resistance
por: Chow, Ariel Ka-Man, et al.
Publicado: (2013)

MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2016)

Rage induces hepatocellular carcinoma proliferation and sorafenib resistance by modulating autophagy
por: Li, Jun, et al.
Publicado: (2018)

The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects
por: Tang, Weiwei, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qbovf4c2gp89d30p5ea4b6dq27